Mirtazapina Viatris Pharmaceuticals (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapina Viatris Pharmaceuticals, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral dosage form for oral use. It is prescribed for the treatment of major depressive disorder in adults.

GNH USA supplies Mirtazapina Viatris Pharmaceuticals as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine acts on depressive disorders and related mood conditions.

- Major depressive disorder: reduces depressive symptoms and improves mood. - Bipolar depression (adjunct therapy): helps stabilize depressive episodes when used with mood stabilizers. - Depression with insomnia: alleviates depressive symptoms while promoting sleep.

Mirtazapine may cause a range of adverse reactions.

Common Side Effects: - Sedation or drowsiness. - Increased appetite and weight gain. - Dry mouth. - Constipation. - Dizziness. - Peripheral edema.

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia. - Hypersensitivity reactions including rash or angioedema. - Suicidal thoughts, especially early in treatment. - Seizures. - Hepatotoxicity. - Cardiac arrhythmias.

Before initiating therapy, consider the following safety measures.

- Monitor weight: watch for significant weight gain. - Assess mood: observe for emergence of suicidal ideation. - Evaluate liver function: periodic liver enzyme testing is advisable. - Caution with CNS depressants: avoid excessive sedation when combined with alcohol or other sedatives. - Pregnancy and lactation: use only if benefits outweigh risks. - Store at room temperature (below 25°C): keep in the original pack, protect from moisture.

Mirtazapine can interact with several drug classes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome. - Linezolid or other reversible MAO inhibitors. - Central nervous system depressants (e.g., benzodiazepines, opioids): heightened sedation.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (SSRIs) or SNRIs: possible additive serotonergic effects. - CYP2D6 inhibitors (e.g., fluoxetine, quinidine): may increase mirtazapine plasma levels. - Antihistamines: may enhance sedation and anticholinergic burden.